Preventive Effects of Phenolic Compound Extra Virgin Olive Oil (EVOO) on the Incidence of Hand Foot Syndrome Induced Capecitabine
DOI:
https://doi.org/10.32539/bsm.v6i1.432Keywords:
Hand foot syndrome, Capecitabine, Extra virgin olive oil, Phenolic compound, AntioxidantAbstract
Hand foot syndrome (HFS) is a reaction that occurs on the skin of the palms and soles. feet, caused by the toxicity of chemotherapy drugs with symptoms such as tingling, pain, erythema, dry skin, swelling, increased pigmentation and itching. This condition is still a problem in the treatment of patients given capecitabine. Although HFS does not cause death, in severe cases it can affect the quality of treatment and interfere with daily activities. The cause of HFS is still unclear but from research it is known that capecitabine and its metabolites will increase the expression of the COX-2 enzyme, inhibit the arachidonic pathway, increase PGE2 activity, causing inflammatory reactions in the form of erythema, edema and pain. The phenolic components contained in EVOO, namely oleocanthal and hydroxytyrosol compounds in several studies have the same properties as celecoxib and ibuprofen as anti-COX-2, will inhibit the arachidonic synthesis pathway, reduce prostaglandin activity and reduce inflammatory reactions.
Authors
- Yenny Dian Andayani1*
- Mgs Irsan Saleh2
- 1Doctoral Programme, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia / Department of Internal Medicine, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
- 2Department of Pharmacology, Faculty of Medicine, Universitas Sriwijaya, Palembang, Indonesia
Corresponding author Yenny Dian Andayani — ydianandayani@gmail.com
Article history
- Submitted
- Accepted
- Published
Downloads
Published
Issue
Section
License
Copyright and licensing
Copyright in each article remains with the author(s). Authors grant Bioscientia Medicina: Journal of Biomedicine and Translational Research a non-exclusive right of first publication and the right to identify itself as the original publisher. No exclusive transfer of copyright is required.
All articles are published under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0): https://creativecommons.org/licenses/by-nc-sa/4.0/. Users may copy, redistribute, remix, transform, and build upon the material for non-commercial purposes, provided appropriate attribution is given, a link to the license is supplied, changes are indicated, and adaptations are distributed under the same license.
The license applies to the article's scholarly content unless a credit line states otherwise. Third-party material may be subject to separate rights. Authors retain patent, trademark, moral, and research-data rights. The copyright year follows the article's publication date.
